Trade CNS Pharmaceuticals, Inc. - CNSP CFD
Add to favourite- Summary
- Historical Data
Spread | 0.0016 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024207% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 0.001 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 0.1027 |
Open | 0.0971 |
1-Year Change | -95.13% |
Day's Range | 0.0962 - 0.1099 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 9, 2024 | 0.1066 | 0.0070 | 7.03% | 0.0996 | 0.1101 | 0.0960 |
Dec 6, 2024 | 0.1027 | 0.0021 | 2.09% | 0.1006 | 0.1027 | 0.0952 |
Dec 5, 2024 | 0.1008 | -0.0063 | -5.88% | 0.1071 | 0.1071 | 0.0996 |
Dec 4, 2024 | 0.1051 | 0.0030 | 2.94% | 0.1021 | 0.1051 | 0.1007 |
Dec 3, 2024 | 0.1029 | -0.0057 | -5.25% | 0.1086 | 0.1086 | 0.0986 |
Dec 2, 2024 | 0.1102 | -0.0004 | -0.36% | 0.1106 | 0.1113 | 0.1046 |
Nov 29, 2024 | 0.1110 | -0.0026 | -2.29% | 0.1136 | 0.1146 | 0.1096 |
Nov 27, 2024 | 0.1138 | -0.0009 | -0.78% | 0.1147 | 0.1170 | 0.1116 |
Nov 26, 2024 | 0.1151 | 0.0045 | 4.07% | 0.1106 | 0.1168 | 0.1106 |
Nov 25, 2024 | 0.1128 | -0.0084 | -6.93% | 0.1212 | 0.1212 | 0.1102 |
Nov 22, 2024 | 0.1125 | -0.0100 | -8.16% | 0.1225 | 0.1234 | 0.1096 |
Nov 21, 2024 | 0.1275 | -0.0023 | -1.77% | 0.1298 | 0.1436 | 0.1256 |
Nov 20, 2024 | 0.1236 | 0.0013 | 1.06% | 0.1223 | 0.1358 | 0.1197 |
Nov 19, 2024 | 0.1244 | 0.0098 | 8.55% | 0.1146 | 0.1341 | 0.1116 |
Nov 18, 2024 | 0.1185 | 0.0159 | 15.50% | 0.1026 | 0.1235 | 0.1026 |
Nov 15, 2024 | 0.1035 | -0.0117 | -10.16% | 0.1152 | 0.1157 | 0.1011 |
Nov 14, 2024 | 0.1164 | -0.0041 | -3.40% | 0.1205 | 0.1235 | 0.1146 |
Nov 13, 2024 | 0.1221 | -0.0006 | -0.49% | 0.1227 | 0.1273 | 0.1155 |
Nov 12, 2024 | 0.1264 | 0.0003 | 0.24% | 0.1261 | 0.1362 | 0.1218 |
Nov 11, 2024 | 0.1257 | 0.0095 | 8.18% | 0.1162 | 0.1362 | 0.1127 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
CNS Pharmaceuticals, Inc. Company profile
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals Inc. is a clinical pharmaceutical company. The Company is focused on development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The Company is developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. The Company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, CNS Pharmaceuticals Inc revenues was not reported. Net loss increased 48% to $14M. Higher net loss reflects Research and development increase of 85% to $9.3M (expense), Selling/General/Admin Expense increase of 7% to $4.7M (expense), Interest expense increase from $3K to $9K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.57 to -$0.53.
Industry: | Biotechnology & Medical Research (NEC) |
2100 West Loop S Ste 900
HOUSTON
TEXAS 77027-3522
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
09:32, 4 December 2024Silver price forecast 2025 and beyond: Third party price target
Rising interest rates and a strong dollar pushed silver to a two-year last September, but what lies ahead?
16:00, 3 December 2024Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
16:41, 28 November 2024Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com